4. Issues of Ethnopharmacology in HIV Management
Summary
To begin to take over a target cell’s genetic material, HIV must overcome the barriers of its own and the host cell’s membranes, using 3 steps that cause structural changes in the envelope protein of HIV so that it can attach to a coreceptor (either CCR5 or CXCR4) on the host cell’s surface, followed by membrane fusion. Viruses that can use CCR5 to infect cells are known as R5 viruses, those that use CXCR4 are known as X4 viruses, and those that can use either coreceptor are termed R5/X4 or dual/mixed viruses.
Differences in the expression of CCR5 are associated with differences in how susceptible a person is to HIV infection and in how rapidly disease may progress after infection. One of the pairs of alleles that encode for the CCR5 coreceptor can occur in a mutated form, Δ32. People with one of the forms of Δ32 make up approximately 10% to 15% of the white population and typically either are resistant to HIV infection or experience slower disease progression. They can, however, still become infected with X4 virus. Generally speaking, R5 virus predominates in patients with less advanced HIV disease, whereas X4 virus emerges at later stages of infection and is associated with more rapid disease progression.
Patients with non-clade B HIV-1 may have different incidences of the predominance or emergence of R4 virus (the overwhelming majority of infections in the Americas and Western Europe are clade B). Clinicians managing patients from areas where non-clade-B infections predominate should be aware that such patients may have HIV disease from a different clade than most of their patients; this can affect which treatment regimens are most appropriate.
Therefore, practitioners need to investigate in a culturally and linguistically sensitive manner the racial and geographic background of their patients to fully understand the context in which they will be developing an antiretroviral management approach for each individual.
CCR5 antagonists—such as maraviroc, the only FDA-approved drug in this class—bind only to the CCR5 coreceptor by altering the coreceptor’s structure so that most strains of HIV cannot recognize it. This binding eliminates the CCR5 trigger needed for membrane fusion, which then cannot occur. Use of a CCR5 antagonist first requires that a viral tropism assay be performed, by either phenotypic testing or genotypic sequencing. If the tropism assay indicates the presence of only R5 virus, a CCR5 antagonist can be included as part of a combination regimen. If a patient’s viral population contains X4 or dual/mixed virus, clinicians should not prescribe a CCR5 antagonist. The guidelines for antiretroviral use recommend that tropism be assessed when a patient experiences virologic failure on a regimen containing a CCR5 antagonist.